Hansa Medical Ab Malmo(HNSBF)

Description: Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an IgG-degrading enzyme of Streptococcus pyogenes (IdeS), an antibody cleaving enzyme for enabling kidney transplantations in sensitized patients, as well as for anti-GBM antibody disease and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), a cancer immunotherapy. The company also has licensing agreement with Axis-Shield Diagnostics Limited for Heparin Binding Protein (HBP)-assay, a method that predicts severe sepsis in emergency clinics. Hansa Biopharma AB (publ) is headquartered in Lund, Sweden.

---

Keywords: Medicine Cancer Biopharmaceutical Immunology Antibodies Immunotherapy Autoimmune Disease Cancer Immunotherapy Transplantation Enzymes Glycoproteins Kidney Sepsis Icts Heparin And Cancer Axis Dosing Transplant Rejection Immunoglobulin G Guillain Barré Syndrome Anti Gbm Antibody Disease Guillain–Barré Syndrome Kidney Transplantations Streptococcus

---

Home Page: www.hansabiopharma.com

ScheelevAegen 22
Lund, 223 63
Sweden
Phone: 46 46 16 56 70

---

Officers

Exchange: PINK

Country: US : United States of America

Currency: US Dollar ($)